Skip to main content
Clinical Trials/NCT01218828
NCT01218828
Completed
Phase 3

Hydration With Different Sodium Chloride Protocols for the Prevention of Contrast Medium-induced Nephropathy in Patients Undergoing Coronary Angiography: a Randomized Trial

Kaiser Permanente1 site in 1 country396 target enrollmentOctober 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Contrast Medium-induced Nephropathy
Sponsor
Kaiser Permanente
Enrollment
396
Locations
1
Primary Endpoint
Contrast induced nephropathy
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Using a randomized controlled trial design, two hydration protocols for the prevention of contrast medium-induced nephropathy will be tested.

Detailed Description

The study population will be recruited from subjects undergoing cardiac catheterization. Subjects will be randomized to one of two hydration protocols: 1. normal saline at 3 mL/kg for one hour prior to contrast exposure and 1.5 mL/kg/hr during and for four hours post procedure. 2. normal saline at 3 mL/kg for one hour prior to contrast exposure and then the fluid rate would be adjusted according to the left ventricular end diastolic pressure (LVEDP). The fluid rate based upon the LVEDP measurement is maintained during the procedure and for four hours post procedure. The LVEDP hydration strategy follows: (2A) \< 13 mmHg, 5 mL/kg/hr during and for four hours post procedure. (2B) 13-18 mmHg, 3 mL/kg during and for four hours post procedure. (2C) \> 18 mmHg, 1.5 mL/kg during and four hours post procedure. Renal function assessment will be made using standard laboratory measures post procedure.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
January 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • estimated GFR less than or equal to 60 mL/min/1.73 m\^2
  • age greater than 18 years
  • at least one of the following: diabetes mellitus, history of congestive heart failure, hypertension, or age greater than 75 years.

Exclusion Criteria

  • patients unable to give consent
  • undergoing emergency cardiac catheterization
  • on renal replacement therapy
  • exposure to contrast media within the prior two days
  • pulmonary edema or active congestive heart failure
  • kidney transplant status
  • severe valvular abnormalities
  • change in serum creatinine greater than 15% over the prior two days

Outcomes

Primary Outcomes

Contrast induced nephropathy

Time Frame: Within four days of contrast exposure

Secondary Outcomes

  • Renal replacement therapy, myocardial infarction, all-cause mortality(30 days and long-term)

Study Sites (1)

Loading locations...

Similar Trials